Status:
COMPLETED
Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
To study the effect of the P-glycoprotein inhibitor ritonavir on the pharmacokinetics (PK) of afatinib depending on the timepoint of ritonavir administration
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 1\. healthy male subjects
- Exclusion criteria:
- 1\. any relevant deviation from healthy conditions
Exclusion
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01426958
Start Date
August 1 2011
Last Update
June 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1200.151.1 Boehringer Ingelheim Investigational Site
Biberach, Germany